|
25. May 2016 - 09:00 am |
Boehringer Ingelheim increases access to the medication for the treatment of HIV/Aids
|
|
28. Sep 2016 - 02:00 pm |
BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS
|
|
22. Nov 2016 - 03:00 pm |
Glyxambi® (empagliflozin/linagliptin) approved for adults with type 2 diabetes in the European Union
|
|
17. Mar 2017 - 01:00 pm |
First dedicated outcome trials of empagliflozin in chronic heart failure initiated
|
|
30. Mar 2017 - 02:00 pm |
Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries
|
|
03. Aug 2017 - 10:00 am |
Next generation of veterinary scientists gathers at National Institutes of Health for National Veterinary Scholars Symposium
|
|
12. Dec 2017 - 02:00 pm |
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer
|
|
03. Jan 2018 - 02:00 pm |
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
|
|
26. Mar 2018 - 10:00 am |
Three leading animal health companies join hands to launch world-class vaccine joint venture targeting foot-and-mouth disease in China
|
|
28. Mar 2018 - 10:00 am |
Boehringer Ingelheim announces 2018 BVDzero Case Awards
|
|
04. Apr 2018 - 06:00 pm |
New Immuno-Oncology Partnership with OSE Immunotherapeutics to Develop a Pioneering Checkpoint Inhibitor
|
|
11. Apr 2018 - 02:00 pm |
Boehringer Ingelheim to invest 65 million euros in avian vaccines in France
|
|
16. Apr 2018 - 02:00 pm |
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease
|
|
25. Apr 2018 - 01:30 pm |
Boehringer Ingelheim R&D pushes to transcend disease boundaries
|
|
15. May 2018 - 12:00 pm |
Boehringer Ingelheim inaugurates its new integrated Asian Veterinary Research & Development Center
|
|
17. May 2018 - 09:00 am |
Boehringer Ingelheim Expert Forum on Farm Animal Well-Being 2018
|
|
01. Jun 2018 - 10:15 am |
Real-world analysis demonstrates Giotrif®/Gilotrif® (afatinib) dose adjustments reduced the frequency and intensity of adverse drug reactions without impacting efficacy
|
|
18. Jun 2018 - 10:00 am |
European Metacam® indication expanded to guinea pigs
|
|
10. Jul 2018 - 10:00 am |
Boehringer Ingelheim invests more than 200 million euros to establish strategic production center for Veterinary Public Health in France
|
|
01. Aug 2018 - 10:00 am |
Boehringer Ingelheim achieves modest growth in the first half of 2018
|
|
06. Aug 2018 - 08:00 am |
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
|
|
09. Aug 2018 - 09:00 am |
Boehringer Ingelheim completes enrolment of GioTag real-world study
|
|
04. Sep 2018 - 10:00 am |
Boehringer Ingelheim launches the first liquid solution for hypertension in cats
|
|
04. Sep 2018 - 02:00 pm |
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
|
|
13. Sep 2018 - 08:00 am |
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
|
|
27. Sep 2018 - 08:00 am |
New vaccine against Bovine Respiratory Disease: Boehringer Ingelheim reaffirms its focus on prevention
|
|
28. Sep 2018 - 08:00 am |
Boehringer Ingelheim is committed to joining forces in the global fight against rabies
|
|
11. Oct 2018 - 07:00 am |
2018 Animal Welfare Medals: Boehringer Ingelheim recognises outstanding research in animal health
|
|
12. Oct 2018 - 10:00 am |
Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South India
|
|
12. Oct 2018 - 01:00 pm |
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in France
|
|
19. Oct 2018 - 12:00 pm |
Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
|
|
26. Oct 2018 - 11:00 am |
Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animals
|
|
15. Nov 2018 - 12:30 pm |
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
|
|
22. Nov 2018 - 08:00 am |
Boehringer Ingelheim partners with Ipsos to gain insights on human-animal bond in Europe
|
|
28. Nov 2018 - 08:00 am |
Boehringer Ingelheim announces two new claims for Nexgard® and Nexgard Spectra® in the EU and Australia
|
|
04. Dec 2018 - 01:00 pm |
Boehringer Ingelheim launches "LastMile" initiative in Sub-Saharan Africa
|
|
11. Dec 2018 - 09:00 am |
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
|
|
13. Dec 2018 - 08:00 am |
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK® HVT + IBD since 2006
|
|
17. Dec 2018 - 10:00 am |
Boehringer Ingelheim launches a tool to aid in the prevention of African swine fever
|
|
18. Dec 2018 - 09:30 am |
Boehringer Ingelheim and the Muskan Foundation inaugurate facility for children with multiple disabilities
|
|
03. Jan 2019 - 01:00 pm |
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
|
|
03. Jan 2019 - 03:00 pm |
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies
|
|
04. Jan 2019 - 01:00 pm |
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
|
|
17. Jan 2019 - 12:00 pm |
Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacities
|
|
21. Jan 2019 - 11:00 am |
A healthy 2019: Four paws for more relaxation and exercise
|
|
24. Jan 2019 - 08:00 am |
Boehringer Ingelheim launches first veterinary vaccines produced in China
|
|
24. Jan 2019 - 09:30 am |
Boehringer Ingelheim partners with AMPATH to scale up knowledge, skills and training for healthcare providers in Kenya
|
|
11. Feb 2019 - 08:00 am |
Boehringer Ingelheim reaffirms its leading position in hatchery vaccination IPPE 2019
|
|
12. Feb 2019 - 02:00 pm |
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
|
|
14. Feb 2019 - 12:30 pm |
Boehringer Ingelheim and Lilly’s CAROLINA® cardiovascular outcome trial for Trajenta® meets primary endpoint of non-inferiority compared to glimepiride
|
|
25. Feb 2019 - 10:00 am |
New Chief Medical Officer appointed
|
|
26. Feb 2019 - 09:00 am |
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development
|
|
28. Feb 2019 - 09:00 am |
Boehringer Ingelheim launches Frontline Flagship Store on Tmall
|
|
07. Mar 2019 - 07:55 am |
Novel antibody shows potential to transform treatment of rare form of psoriasis
|
|
18. Mar 2019 - 01:00 pm |
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
|
|
22. Mar 2019 - 08:00 am |
World Water Day - Making every drop count
|
|
28. Mar 2019 - 08:00 am |
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019
|
|
29. Mar 2019 - 01:00 pm |
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
|
|
01. Apr 2019 - 10:00 am |
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
|
|
02. Apr 2019 - 09:00 am |
Boehringer Ingelheim launches BVDzero scholarship for veterinary students
|
|
03. Apr 2019 - 11:00 am |
Why we may be more like our pets than we think
|
|
03. Apr 2019 - 11:00 am |
Positivity… just a paw away
|
|
03. Apr 2019 - 11:00 am |
Boehringer Ingelheim celebrates its ‘uniqueness’ by championing both human and animal health in new campaign
|
|
09. Apr 2019 - 09:00 am |
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
|
|
11. Apr 2019 - 08:00 am |
Major investment for respiratory diseases completed
|
|
11. Apr 2019 - 09:00 am |
Boehringer Ingelheim celebrates 20 years of Metacam® for cattle
|
|
15. Apr 2019 - 01:00 am |
New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease
|
|
15. Apr 2019 - 09:00 am |
Independent large real-world study comparing NOACs in AF-patients
|
|
15. Apr 2019 - 09:00 am |
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
|
|
17. Apr 2019 - 10:30 am |
Financial year 2018: Boehringer Ingelheim grows and invests
|
|
02. May 2019 - 01:00 pm |
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program
|
|
14. May 2019 - 12:00 pm |
Digital transformation: Boehringer Ingelheim fosters cooperation with innovative partners
|
|
16. May 2019 - 10:30 am |
Trial results of Pradaxa® vs ASA in ESUS published in NEJM
|
|
20. May 2019 - 08:00 am |
Veterinary oncology experts from Europe, Japan and the US meet in Germany
|
|
20. May 2019 - 06:00 pm |
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
|
|
23. May 2019 - 12:00 pm |
Network of 1,500 stroke-ready clinics across Europe
|
|
27. May 2019 - 09:00 am |
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
|
|
29. May 2019 - 11:00 am |
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
|
|
03. Jun 2019 - 09:30 am |
Boehringer Ingelheim and PharmAccess launch digital healthcare program in Kenya
|
|
04. Jun 2019 - 08:00 am |
Boehringer Ingelheim partners with Constantia Flexibles to provide augmented reality packaging experience
|
|
10. Jun 2019 - 07:00 pm |
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria
|
|
11. Jun 2019 - 03:30 am |
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
|
|
11. Jun 2019 - 12:00 pm |
The healthcare of tomorrow:
Boehringer Ingelheim relies on digital transformation
|
|
11. Jun 2019 - 02:00 pm |
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
|
|
17. Jun 2019 - 09:00 am |
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
|
|
17. Jun 2019 - 06:00 pm |
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody,
BI 765063, in Patients with Advanced Solid Tumors
|
|
20. Jun 2019 - 09:00 am |
Collaboration key to meeting consumers’ expectations for better animal welfare
|
|
26. Jun 2019 - 12:00 pm |
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failure
|
|
01. Jul 2019 - 02:00 pm |
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
|
|
04. Jul 2019 - 08:30 am |
FRONTLINE® becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
|
|
08. Jul 2019 - 10:00 am |
Speech recognition can detect warning signals for schizophrenia or Alzheimer's dementia
|
|
09. Jul 2019 - 08:00 am |
Dabigatran’s safety and efficacy established for management of VTE in children
|
|
15. Jul 2019 - 02:00 pm |
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
|
|
18. Jul 2019 - 02:00 pm |
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
|
|
18. Jul 2019 - 03:00 pm |
INMARK® results suggest prompt treatment of IPF with antifibrotics to slow disease progression
|
|
01. Aug 2019 - 10:00 am |
First half 2019: High levels of investment in R&D and robust organic growth
|
|
02. Aug 2019 - 11:30 am |
Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
|
|
12. Aug 2019 - 03:00 pm |
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
|
|
13. Aug 2019 - 09:00 am |
Boehringer Ingelheim opens Health Management Centre in China
|
|
19. Aug 2019 - 10:00 am |
Social entrepreneurs improve healthcare access across the African continent
|
|
26. Aug 2019 - 01:53 pm |
Change in the Board of Managing Directors at Boehringer Ingelheim
|
|
30. Aug 2019 - 09:00 am |
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
|
|
03. Sep 2019 - 08:00 am |
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
|
|
04. Sep 2019 - 08:00 am |
Results from RE-SPECT CVT® published - first trial of NOAC in cerebral venous thrombosis
|
|
04. Sep 2019 - 09:00 am |
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
|
|
09. Sep 2019 - 03:30 pm |
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
|
|
12. Sep 2019 - 09:00 am |
Boehringer Ingelheim showcases its leading avian vaccines and services at WVPAC 2019
|
|
19. Sep 2019 - 12:15 pm |
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors
|
|
20. Sep 2019 - 01:00 pm |
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
|
|
20. Sep 2019 - 02:00 pm |
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
|
|
26. Sep 2019 - 08:00 am |
Boehringer Ingelheim donates vaccines to help fight rabies
|
|
27. Sep 2019 - 08:30 am |
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
|
|
30. Sep 2019 - 08:00 am |
INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1
|
|
01. Oct 2019 - 09:00 am |
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
|
|
01. Oct 2019 - 09:00 am |
New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes
|
|
07. Oct 2019 - 09:00 am |
Winners of the 2019 European PRRS Research Award announced
|
|
10. Oct 2019 - 03:25 pm |
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
|
|
16. Oct 2019 - 02:00 pm |
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
|
|
29. Oct 2019 - 11:30 am |
Boehringer Ingelheim joins forces with The Defeat-NCD Partnership to fight non-communicable diseases
|
|
29. Oct 2019 - 03:00 pm |
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
|
|
04. Nov 2019 - 03:00 pm |
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
|
|
05. Nov 2019 - 09:00 am |
The new African Swine Fever Manual published
|
|
07. Nov 2019 - 09:00 am |
Boehringer Ingelheim becomes an official partner to CatCareforLife
|
|
12. Nov 2019 - 02:30 pm |
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised.
|
|
17. Nov 2019 - 04:50 pm |
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
|
|
09. Dec 2019 - 09:00 am |
Boehringer Ingelheim announces 2020 BVDzero Case Awards
|
|
13. Dec 2019 - 02:00 pm |
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure
|
|
18. Dec 2019 - 08:00 am |
Boehringer Ingelheim discontinues development of BI 1467335 for NASH
|
|
30. Dec 2019 - 10:30 am |
Milestone for Biopharmaceuticals in China
|
|
03. Jan 2020 - 09:00 am |
Introducing DiaTEC, a new purification technology for Ingelvac CircoFLEX®
|
|
09. Jan 2020 - 01:00 pm |
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
|
|
04. Feb 2020 - 07:00 am |
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
|
|
06. Feb 2020 - 08:30 am |
Respimat® re-usable inhaler wins 2020 Pharmapack Eco-Design Award
|
|
12. Feb 2020 - 11:00 am |
CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes
|
|
17. Feb 2020 - 08:00 am |
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
|
|
18. Feb 2020 - 03:00 pm |
Boehringer Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox
|
|
27. Feb 2020 - 04:00 pm |
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
|
|
28. Feb 2020 - 12:40 pm |
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
|
|
12. Mar 2020 - 01:00 pm |
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease
|
|
16. Mar 2020 - 08:00 am |
The World Association for Buiatrics and Boehringer Ingelheim announce the 'Ruminant Well-Being Awards’
|
|
16. Mar 2020 - 09:00 am |
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib
|
|
20. Mar 2020 - 10:10 pm |
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
|
|
30. Mar 2020 - 10:00 am |
Boehringer Ingelheim opens second branch of digital lab BI X in Shanghai
|
|
08. Apr 2020 - 08:00 am |
Covid Global Support Program
|
|
08. Apr 2020 - 10:00 am |
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
|
|
09. Apr 2020 - 11:00 am |
Boehringer Ingelheim Biopharmaceuticals China receives “Facility of the Year” Award
|
|
14. Apr 2020 - 08:00 am |
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
|
|
21. Apr 2020 - 08:00 am |
Aservo® EquiHaler® wins Red Dot for outstanding design quality
|
|
21. Apr 2020 - 08:15 am |
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
|
|
21. Apr 2020 - 09:00 am |
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
|
|
13. May 2020 - 02:00 pm |
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
|
|
14. May 2020 - 02:00 pm |
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
|
|
25. May 2020 - 05:00 pm |
Winners of 2020 BVDzero Case Awards announced
|
|
26. May 2020 - 01:55 pm |
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
|
|
29. May 2020 - 01:00 pm |
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1
|
|
04. Jun 2020 - 08:00 am |
“LastMile” – improving through digital
|
|
08. Jun 2020 - 02:00 pm |
New consortium EUbOPEN will provide tools to unlock disease biology
|
|
25. Jun 2020 - 08:00 am |
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
|
|
29. Jun 2020 - 01:00 pm |
Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetes
|
|
02. Jul 2020 - 03:00 pm |
Boehringer Ingelheim Launches External Innovation Hub in China
|
|
07. Jul 2020 - 02:00 pm |
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
|
|
09. Jul 2020 - 02:30 pm |
Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action Fund
|
|
09. Jul 2020 - 03:55 pm |
Perceived burden of disease is greater in younger people living with COPD, global survey reveals
|
|
15. Jul 2020 - 02:45 pm |
European Commission approves third nintedanib indication in pulmonary fibrosis1
|
|
27. Jul 2020 - 10:00 am |
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health
|
|
30. Jul 2020 - 12:15 pm |
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
|
|
03. Aug 2020 - 08:30 am |
First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer Ingelheim
|
|
12. Aug 2020 - 02:00 pm |
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
|
|
17. Aug 2020 - 09:00 am |
Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship
|
|
18. Aug 2020 - 08:00 am |
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
|
|
27. Aug 2020 - 03:00 pm |
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
|
|
02. Sep 2020 - 02:00 pm |
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
|
|
07. Sep 2020 - 08:00 am |
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic Retinopathy
|
|
10. Sep 2020 - 02:00 pm |
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
|
|
11. Sep 2020 - 01:00 pm |
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
|
|
14. Sep 2020 - 01:30 pm |
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
|
|
16. Sep 2020 - 04:15 pm |
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020
|
|
17. Sep 2020 - 02:00 pm |
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
|
|
28. Sep 2020 - 09:30 am |
World Rabies Day 2020: eliminating rabies through sustainable programs
|
|
29. Sep 2020 - 05:30 am |
Boehringer Ingelheim invests in partnership to further develop the pet market in China
|
|
30. Sep 2020 - 09:00 am |
Boehringer Ingelheim and Fraunhofer IME launch collaboration
|
|
05. Oct 2020 - 09:00 am |
Study shows vaccinating results in increased milk production
|
|
07. Oct 2020 - 09:00 am |
Winners of the 2020 European PRRS Research Award
|
|
14. Oct 2020 - 02:00 pm |
Expanded alliance with OBT advances cancer immunology pipeline
|
|
22. Oct 2020 - 09:00 am |
Purevax® range now available in 0.5 ml presentation
|
|
27. Oct 2020 - 09:00 am |
Partnership leads to innovative needle free injection device for pigs
|
|
28. Oct 2020 - 01:00 pm |
Developing potential treatment for severe COVID19 complications
|
|
05. Nov 2020 - 04:00 pm |
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
|
|
16. Nov 2020 - 09:00 am |
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
|
|
18. Nov 2020 - 02:00 pm |
New: Empagliflozin reduced risk of recurrent CV events
|
|
01. Dec 2020 - 10:00 am |
Boehringer Ingelheim: Digital Lab BI X Facilitates Global Partnerships
|
|
07. Dec 2020 - 08:00 am |
Boehringer Ingelheim becomes member of IPC
|
|
07. Dec 2020 - 02:00 pm |
Collaboration with Proxygen on Molecular Glue Degraders
|
|
09. Dec 2020 - 10:00 am |
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen
|
|
10. Dec 2020 - 02:00 pm |
Boehringer Ingelheim to acquire NBE-Therapeutics
|
|
18. Dec 2020 - 02:00 pm |
SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
|
